- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed submits ultrasound contrast NDA
Contrast agent developer Nycomed Amersham hopes soon to join the ultrasound contrast race. The Buckingham, U.K.-based firm has submitted a new drug application (NDA) to the Food and Drug Administration for Sonazoid, an ultrasound contrast agent formerly
Contrast agent developer Nycomed Amersham hopes soon to join the ultrasound contrast race. The Buckingham, U.K.-based firm has submitted a new drug application (NDA) to the Food and Drug Administration for Sonazoid, an ultrasound contrast agent formerly called NC100100. In support of its application, Nycomed has submitted clinical data demonstrating echocardiographic improvement in endocardial border delineation and left ventricular opacification when Sonazoid is used. Nycomed performed clinical trials for the agent on approximately 1300 patients in Europe and the U.S.
Nycomed has been defending patents covering the agents technology since 1997, when it became embroiled in a dispute with San Diego-based Molecular Biosystems and St. Louis-based Mallinckrodt (SCAN 4/29/98).
Developed for use in such cardiology and radiology applications as heart and liver imaging, Sonazoid is also being investigated for use in imaging myocardial perfusion. The companys Japanese partner in ultrasound contrast agent R&D, Daiichi Pharmaceutical, has completed phase I trials for liver and heart imaging applications for Sonazoid. Nycomed plans to submit an equivalent clearance document for the agent in Europe later this year.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
